A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck cancer

被引：8
作者：
Seiwert, Tanguy Y.
Cohen, Ezra E. W.
Haraf, Daniel J.
Stenson, Kerstin
Blair, Elizabeth A.
Mauer, Ann
Dekker, Allison
Vokes, Everett E.
机构：
[1] Univ Chicago, Hematol Oncol Sect, Canc Res Ctr, Chicago, IL 60637 USA
[2] Univ Chicago, Dept Radiat Oncol, Chicago, IL 60637 USA
[3] Univ Chicago, Dept Surg Otorhinolaryngol, Chicago, IL 60637 USA
来源：
CANCER INVESTIGATION | 2007年 / 25卷 / 06期
关键词：
phase I; locally advanced head and neck cancer; docetaxel; chemoradiotherapy; induction chemotherapy; 5-FU; hydroxyurea;
D O I：
10.1080/07357900701357993
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The purpose of this study was to determine the maximum tolerated dose (MTD) of docetaxel based induction and concomitant chemoradiotherapy (CRT) after using the FHX platform (5 = 5-FU, H = hydroxyurea, X = Radiation). Patients with Stage III/IV locally advanced HNSCC were enrolled. Induction chemotherapy (carboplatin/docetaxel) was followed by 5 cycles of concomitant docetaxel based CRT. No DLTs were observed in dose levels 1/2 for induction and CRT. Dose level 2 was expanded. The overall survival CR rate after CRT was 79 percent. Median overall (OS) has not been reached and 2-year OS is 80.7 percent. The recommended Phase II dose of docetaxel with FHX CRT is 25 mg/m(2) and 35 mg/m(2) in combination with carboplatin induction (AUC = 6).
引用
收藏
页码：435 / 444
页数：10
相关论文
共 46 条
  • [1] AAMDAL SHM, 1998, AM SOC CLIN ONC ANN, V17, pA476
  • [2] [Anonymous], P AM SOC CLIN ONCOL
  • [3] A CONFIDENCE-INTERVAL FOR THE MEDIAN SURVIVAL-TIME
    BROOKMEYER, R
    CROWLEY, J
    [J]. BIOMETRICS, 1982, 38 (01) : 29 - 41
  • [4] Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer:: a Spanish Lung Cancer Group trial
    Camps, C
    Massuti, B
    Jiménez, A
    Maestu, I
    Gómez, RG
    Isla, D
    González, JL
    Almenar, D
    Blasco, A
    Rosell, R
    Carrato, A
    Viñolas, N
    Batista, N
    Girón, CG
    Galán, A
    López, M
    Blanco, R
    Provencio, M
    Diz, P
    Felip, E
    [J]. ANNALS OF ONCOLOGY, 2006, 17 (03) : 467 - 472
  • [5] CARTER DL, 2003, P AN M AM SOC CLIN, V22, P504
  • [6] Phase I trial of outpatient weekly docetaxel, carboplatin and concurrent thoracic radiation therapy for stage III unresectable non-small-cell lung cancer: a Vanderbilt cancer center affiliate network (VCCAN) trial
    Choy, H
    DeVore, RF
    Hande, KR
    Porter, LL
    Rosenblatt, PA
    Slovis, B
    Laporte, K
    Shyr, Y
    Johnson, DH
    [J]. LUNG CANCER, 2001, 34 (03) : 441 - 449
  • [7] Cmelak AJ, 2005, J CLIN ONCOL, V23, p502S
  • [8] Cooper JS, 1998, HEAD NECK-J SCI SPEC, V20, P588, DOI 10.1002/(SICI)1097-0347(199810)20:7<588::AID-HED2>3.3.CO
  • [9] 2-6
  • [10] De Crevoisier R, 2001, CANCER-AM CANCER SOC, V91, P2071, DOI 10.1002/1097-0142(20010601)91:11<2071::AID-CNCR1234>3.0.CO
12345